Ketohexokinase Isoforms in Endometrial Cancer.

NCT03931265 | Unknown

• 1 other identifier: 108009-F
• Study Type: observational
• Target: 220
• Locations: 1 country
• Sites: 1

Brief Summary

Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.

Conditions

Endometrial Cancer

Outcome Measures

Primary Outcomes (1)

• The role of ketohexokinase isoforms in the overall survival of endometrial cancer.

  Cox proportional hazard regression to evaluate the role of ketohexokinase isoforms in the overall survival of endometrial cancer.

  5 years

Secondary Outcomes (1)

• Correlation of ketohexokinase isoforms with the other prognostic risk factors

  5 years

Interventions

ketohexokinase DIAGNOSTIC_TEST

Check the isoforms of ketohexokinase in the specimen of endometrial cancer

Eligibility Criteria

• Age: 20 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Women with endometrial cancer who underwent staging surgeries in the Far Eastern Memorial Hospital

You may qualify if:

• \>20 years
• Women with endometrial cancer who are about to be admitted to hospital for gynecological staging.
• Women who have undergone gynecological staging surgery for endometrial cancer in the past.

You may not qualify if:

• Women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.

Sponsors & Collaborators

• Far Eastern Memorial Hospital: lead
• Gynecologic Oncology Group: collaborator

Study Sites (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

Banqiao District, New Taipei, 22050, Taiwan

RECRUITING

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Central Study Contacts

Sheng-Mou Hsiao, MD

CONTACT

+886289667000; smhsiao2@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief, Department of Obstetrics & Gynecology

Study Record Dates

• First Submitted: April 25, 2019
• First Posted: April 30, 2019
• Study Start: April 11, 2019
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: September 15, 2023

Record last verified: 2023-09

Locations

TW (1)